DOCSLIB.ORG

Paired Comparison of Iopamidol and Iopromide in Hepatic Arteriography1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Paired Comparison of Iopamidol and Iopromide in Hepatic Arteriography1 J Korean Radiol Soc 2003;48:141-145 Paired Comparison of Iopamidol and Iopromide in Hepatic Arteriography1 Young Ho Choi, M.D.2, Jin Wook Chung, M.D., Guk Myung Choi, M.D., Chang Jin Yoon, M.D., Keon Ha Kim, M.D., Seung Gyu Moon, M.D., Hyo-cheol Kim, M.D., Jae Hyung Park, M.D. Purpose: To compare the clinical efficacy of iopamidol 370 and iopromide 370, as used in hepatic arteriography, in terms of their safety, patient tolerance, and image quality. Materials and Methods: Between February and April 2001, 30 patients (M:F=27:3; mean age, 57 years) with hepatocellular carcinoma underwent hepatic angiography in which iopamidol 370 was used for transcatheter arterial chemoembolization (TAE). Sensations of heat or pain following contrast injection, a patient’s distress or discom- fort levels, and any side effects of the contrast media were monitored, and afterwards patients were asked whether they were aware of any differences between iopamidol 370 and iopromide 370, which had been used in hepatic angiography for previous TAE prior to February 2001. Three experienced independent radiologists assessed the diag- nostic efficacy of the contrast media in terms of overall image quality, which was sta- tistically analysed using Wilcoxon’s signed ranks test. Results: No patient experienced sensations of heat or pain during angiography, or showed any objective distress or discomfort, though two suffered mild nausea during angiography with iopamidol 370. None was aware of any difference between iopro- mide 370 and iopamidol 370. In terms of overall image quality, the diagnostic efficacy of contrast media in all patients was‘ good’to‘ excellent’, with no significant differ- ence between iopromide 370 and iopamidol 370 (p>0.05). Conclusion: In hepatic arteriography, the clinical efficacy of iopamidol 370 is compa- rable with that of another nonionic contrast medium, iopromide 370, in terms of safe- ty, tolerance, and image quality. Iopamidol 370 is thus a useful alternative medium. Index words : Contrast media, efficacy study Contrast media, comparative studies Contrast media, angiography The development of contrast media for angiography creased tolerance and good radio-opacity. Since the first has always been directed toward substances with in- nonionic contrast agent was developed in 1969 to over- come the limitations of ionic contrast media that caused 1Department of Radiology, Seoul National University College of Medicine and the Institute of Radiation Medicine, SNUMRC more intense sensations of heat and pain, and cardiac 2 Department of Radiology, Boramae Municipal Hospital toxicity due to high osmolarity (1, 2), ongoing efforts Received March 7, 2002 ; Accepted September 24, 2002 Address reprint requests to : Jin Wook Chung, M.D., Department of have been made to develop media with fewer side ef- Radiology, Seoul National University College of Medicine and the Institute of Radiation Medicine, SNUMRC fects. 28, Yongon-dong, Chongno-gu, Seoul 110-744, Korea. Iopamidol is one of the most widely used nonionic Tel. 82-2-760-2584 Fax. 82-2-743-6385 E-mail: [email protected] contrast media with low osmolarity. To date, many clin- ─ 141 ─ Young Ho Choi, et al : Paired Comparison of Iopamidol and Iopromide in Hepatic Arteri ography ical studies involving its use in aortography (3, 4), pe- unstable or pregnant; had moderate to severe cardiac, ripheral angiography (5-7), cardiac angiography (8- hepatic, or renal failure; suffered from paraproteinemia, 10), cerebral angiography (11, 12), and visceral arteriog- multiple myeloma, thrombocytopenia, or sickle cell raphy (13) have been performed, but to our knowledge, anaemia; had an allergic or hypersensitive condition for none have examined its use in hepatic arteriography. In which a drug had been prescribed; or had received any conjunction with Dong Kook Pharmaceuticals, we other contrast medium within the previous 48 hours, therefore conducted the present investigation. were excluded from the study. In this study, the clinical efficacy of two nonionic con- trast media, iopamidol 370 (PamirayⓇ; Dong Kook, Procedures Seoul, Korea) and iopromide 370 (Ultravist(r); Shering, Before chemoembolization, patients underwent an- Seoul, Korea) was compared in terms of safety, patient giography to determine the location and extent of the tu- tolerance, and image quality (Fig. 1). Iopromide 370 is mor. Local anesthesia with 1% lidocaine was performed one of the nonionic contrast media most widely used in prior to femoral arterial puncture for insertion of an ar- angiographic procedures such as abdominal aortogra- terial sheath. A 5-Fr RH catheter (Cook, Bloomington, phy and visceral arteriography, and its osmolarity and U.S.) was inserted into the aorta and its branches under viscosity are similar to those of iopamidol 370 (Table 1). fluoroscopic guidance, and angiography of the celiac In our study, the two media were used serially during trunk was performed. The amount of contrast medium transcatheter arterial chemoembolizations (TAE) under- used ranged from 42 to 48 mL and the injection rate was gone by each of the patients involved. 7 to 8 mL/second. If it was suspected that an aberrant hepatic artery originated from the superior mesenteric Materials and Methods artery, this was examined angiographically after the in- jection of contrast media at a rate of 6-8 mL/second. Patients Using a 3-Fr microcatheter, if necessary, selective an- Between February and April 2001, 30 patients [M:F = giography of the right or left hepatic, or inferior phrenic 27:3; age, 40-74 (mean, 57) years] in whom hepatocel- artery was performed to determine the exact location of lular carcinoma had been diagnosed prior to February 2001 underwent TAE once using iopamidol 370 after Table 1. written consent to its use had been obtained. Prior to Iopamidol 370 Iopromide 370 February 2001, TAE was performed at least once, using Iodine concentration (mg/mL) 370 370 iopromide 370. Osmolarity (mOsm/kg H2O) 796 780 All patients except one (Patient 28) were in relatively Molecular weight 770 791 good general condition. Any one who were medically Viscocity at 37°C (centipoises) 9.5 9.5 A B Fig. 1. Molecular structure of iopamidol and iopromide. Iopamidol (A) and iopromide (B) have a tri-iodinated benzene ring and three highly hydrophilic side chains. They are stable in solu- tion. ─ 142 ─ J Korean Radiol Soc 2003;48:141-145 the tumor and to clarify the site of its feeding artery. The side effects for at least 24 hours after the completion of amount of contrast media used ranged from 3 to 14 mL, procedures. injected at 0.5-2 mL/second according to the size of the After the conclusion of angiography, patients were vessel. asked whether they were aware of any differences be- The respective amounts of iopromide 370 and iopami- tween iopamidol 370 and iopromide 370, which had dol 370 used were 42-105 (mean, 70.2) and 42-105 been used in hepatic angiography before February 2001. (mean, 68.6) mL, with no statistically significant differ- The safety of iopromide 370 was analysed on the basis ence between the mean volumes. of the answers and the patients’medical records. Angiographic images were obtained using a Siemens Image quality was assessed by three experienced inde- Polytron S-Plus DSA System in conjunction with a pendent radiologists blinded to a patient’s identity and Siemens Angiostar Table equipped with a 13-inch inten- clinical profile and to the contrast media used. In addi- sifier. tion, each was unware of the other radiologists’assess- ment. Using original images, the diagnostic efficacy of Safety and Efficacy Analysis contrast media in terms of overall image quality was as- During hepatic angiography performed using iopami- sessed according to a five-point scale, as follows: 1, poor dol 370 between February and April 2001, patients were opacification; 2, insufficient opacification; 3, sufficient told that sensations of heat or pain might occur after opacification; 4, good opacification; 5, excellent opacifi- contrast injection, and were asked to grade these sensa- cation.“ Poor”indicated that image quality did not per- tions after the whole procedure as ‘none’, ‘mild’, mit diagnosis, and“ excellent”that vessel detail was visi- ‘moderate’or‘ severe’. Investigators used a four-point ble. For statistical analysis of image quality, Wilcoxon’s scale, as follows, to assess the degree of a patient’s dis- signed ranks test was used. Two-sided probability (p) tress or discomfort: 0, no evidence of distress; 1, slight values of <0.05 were considered statistically significant. movement and/or vocal complaint; 2, moderate move- The reproducibility of the three observers’assessment ment and/or vocal complaint; 3, forcible movement of image quality was assigned a ĸ (kappa) value. and/or loud cries. Side effects during the procedures were determined Results by direct questioning and observation. The severity of any side effect was graded as‘ none’,‘ mild’(disappear- No patient experienced sensations of heat or pain dur- ing spontaneously, or no need for therapy),‘ moderate’ ing angiography with either iopromide 370 or iopamidol (necessitating therapy but responding immediately) or 370, or showed any objective distress or discomfort. ‘severe’(alarming or life-threatening, responding poor- Two patients complained that the use of iopamidol 370 ly or slowly to therapy). All patients were monitored for led to mild nausea, though none were aware of any dif- A B Fig. 2. Image quality of hepatic angiography. Two hepatic angiograms were evaluated as“ good opacification”(A) and“ exellent opacification”(B) by all three radiologists. ─ 143 ─ Young Ho Choi, et al : Paired Comparison of Iopamidol and Iopromide in Hepatic Arteri ography ferences between the two media. were collected from just 30 patients, which may have With regard to the reproducibility of observors’as- induced bias. To determine whether iopamidol and oth- sessment of image quality, ĸ values of 0.58, 0.74, and er contrast media, including iopromide, exert different 0.64 was assigned to observers 1 and 2, 1 and 3, and 2 effects because of differences in their formulation or and 3, respectively.
Load more

Recommended publications
  • Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini
    Pharmacologyonline 2: 727-753 (2010) ewsletter Bradu and Rossini COTRAST AGETS - IODIATED PRODUCTS. SECOD WHO-ITA / ITA-OMS 2010 COTRIBUTIO O AGGREGATE WHO SYSTEM-ORGA CLASS DISORDERS AD/OR CLUSTERIG BASED O REPORTED ADVERSE REACTIOS/EVETS Dan Bradu and Luigi Rossini* Servizio Nazionale Collaborativo WHO-ITA / ITA-OMS, Università Politecnica delle Marche e Progetto di Farmacotossicovigilanza, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary From the 2010 total basic adverse reactions and events collected as ADRs preferred names in the WHO-Uppsala Drug Monitoring Programme, subdivided in its first two twenty years periods as for the first seven iodinated products diagnostic contrast agents amidotrizoate, iodamide, iotalamate, iodoxamate, ioxaglate, iohexsol and iopamidol, their 30 WHO-system organ class disorders (SOCDs) aggregates had been compared. Their common maximum 97% levels identified six SOCDs only, apt to evaluate the most frequent single ADRs for each class, and their percentual normalization profiles for each product. The WILKS's chi square statistics for the related contingency tables, and Gabriel’s STP procedure applied to the extracted double data sets then produced profile binary clustering, as well as Euclidean confirmatory plots. They finally showed similar objectively evaluated autoclassificative trends of these products, which do not completely correspond to their actual ATC V08A A, B and C subdivision: while amidotrizoate and iotalamate, and respectively iohesol and iopamidol are confirmed to belong to the A and B subgroups, ioxaglate behaves fluctuating within A, B and C, but iodamide looks surprizingly, constantly positioned together with iodoxamate as binary/ternary C associated. In view of the recent work of Campillos et al (Science, 2008) which throws light on the subject, the above discrepancies do not appear anymore unexpected or alarming.
    [Show full text]
  • ACR Manual on Contrast Media
    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Premedication for Contrast Medium Allergies Factfinder
    Published March 2014 Premedication for Contrast Medium Allergies FactFinder Committed to providing helpful information to International Spine Intervention Society members about key patient safety issues, the Society’s Patient Safety Committee has developed a FactFinder series. FactFinders will explore and debunk myths surrounding patient safety issues. The intent of this FactFinder is to present the evidence regarding the effectiveness of premedication for contrast medium allergies that impact the delivery of spinal procedures. Myth #1: In patients with radiocontrast media (RCM) allergy, it is safe to proceed with RCM injection as long as the patient is premedicated with steroids and antihistamines. Fact: Although premedication likely reduces the risks associated with injecting RCM, no premedication regimen has been proven safe for a RCM allergic reaction. Conclusions & Recommendations The International Spine Intervention Society Guidelines recommend the use of RCM for nearly all spinal diagnostic and treatment procedures.1 An understanding of the severity and frequency of reactions to RCM is paramount prior to discussing premedication. Reactions to RCM are immediate, defined as within the first hour, with 70% occurring within the first five minutes; or late, occurring between one hour and one week later. The late reactions are typically cutaneous.2 There are three types of immediate reactions: mild, moderate, and severe. Mild reactions: include nausea, vomiting, and mild urticaria. These signs and symptoms appear self-limited without evidence of progression. Treatment usually entails only observation and reassurance, however, these reactions may progress into a more severe category. Moderate reactions: include moderate urticaria, vasovagal reaction, mild bronchospasm, and tachycardia. These reactions require treatment, but are not immediately life threatening.
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Immediate Reactions Following Iodinated Contrast Media Injection: a Study of 38 Cases
    European Journal of Radiology 77 (2011) 495–501 Contents lists available at ScienceDirect European Journal of Radiology journal homepage: www.elsevier.com/locate/ejrad Immediate reactions following iodinated contrast media injection: A study of 38 cases Pascale Dewachter a,∗, Dominique Laroche b,1, Claudie Mouton-Faivre c,2, Evelyne Bloch-Morot d,3, Jean-Pierre Cercueil e,4, Liliane Metge f,5, Marie-France Carette g,6, Marie-Claude Vergnaud h,7, Olivier Clément i,8 a Service d’Anesthésie-Réanimation Chirurgicale & SAMU de Paris, Hôpital Necker-Enfants Malades, AP-HP, Université Paris-Descartes, 149 Rue de Sèvres, 75015 Paris, France b Service de Biophysique, Centre Hospitalier Universitaire, Avenue de la Côte de Nacre, Caen, France c Pôle d’Anesthésie-Réanimation Chirurgicale, Centre Hospitalier Universitaire-Hôpital Central, Avenue du Maréchal de Lattre de Tassigny, Nancy, France d Service de Médecine Interne, Hôpital Européen Georges Pompidou, 20 Rue Leblanc, Paris, France e Département d’Imagerie Medicale, Centre Hospitalier Universitaire, Hôpital du Bocage, 2, Boulevard du Maréchal de Lattre de Tassigny, Dijon, France f Département d’Imagerie Médicale, Centre Hospitalier Universitaire Caremeau, Place du Pr Robert Debré, Nîmes, France g Service de Radiologie, Hôpital Tenon, 4 Rue de la Chine, Paris, France h Service de Médecine Polyvalente, Centre Hospitalier Universitaire, Avenue de la Côte de Nacre, Caen, France i Service de Radiologie, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Descartes, 20 Rue Leblanc, Paris, France article info abstract Article history: Objectives: To investigate the pathomechanisms involved in cases of immediate hypersensitivity reactions Received 2 August 2009 occurring after the administration of iodinated contrast media.
    [Show full text]
  • FDA Listing of Established Pharmacologic Class Text Phrases January 2021
    FDA Listing of Established Pharmacologic Class Text Phrases January 2021 FDA EPC Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for Active Moiety Name [indication(s)].” For each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13.
    [Show full text]
  • Chapter 1: Introduction and Background…………………………………………….…...1
    Synthesis and Characterization of Novel Inorganic Nanoparticles for Diagnostic and Therapeutic Applications A dissertation submitted to Kent State University in partial fulfillment of the requirements for the degree of Doctor of Philosophy by Vindya S. Perera December, 2014 Dissertation written by Vindya S. Perera B.S., University of Peradeniya, SriLanka, 2006 Ph.D., Kent State University, USA, 2014 Approved by __________________________________ Songping Huang, Professor, Ph.D., Department of Chemistry & Biochemistry, Doctoral Advisor __________________________________ Scott D. Bunge, Professor, Ph.D., Department of Chemistry & Biochemistry __________________________________ Mietek Jaroniec, Professor, Ph.D., Department of Chemistry & Biochemistry __________________________________ Qi-Huo Wei, Professor, Ph.D., Liquid Crystal Institute __________________________________ Ernest Freeman, Professor, Ph.D., Department of Biological Sciences Accepted by __________________________________ Michael J. Tubergen, Professor, Ph.D., Chair, Department of Chemistry & Biochemistry __________________________________ James L. Blank, Professor, Ph.D., Dean, College of Arts and Sciences TABLE OF CONTENTS List of figures……………………………………………………………………….…..iii List of schemes……………………………………………………………………….....ix List of tables……………………………………………………………………………..x Acknowledgments……………………………………………………………………...xi Chapter 1: Introduction and background…………………………………………….…...1 1.1. Magnetic resonance imaging (MRI)………………………………………….…...1 1.1.1 Contrast agents for MRI……………………………………………………..…...6
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Diagnostic Performance of Gadoxetic Acid
    ® Diagnostic Accuracy Study Medicine OPEN Diagnostic performance of gadoxetic acid (Primovist)-enhanced MR imaging versus CT during hepatic arteriography and portography for small hypervascular hepatocellular carcinoma ∗ Sun Young Yim, MD, PhDa, Beom Jin Park, MD, PhDb, Soon Ho Um, MD, PhDa, , Na Yeon Han, MD, PhDb, Deuk Jae Sung, MD, PhDb, Sung Bum Cho, MD, PhDb, Seung Hwa Lee, MD, PhDb, Min Ju Kim, MD, PhDb, Jin Yong Jung, MDa, Jin Dong Kim, MD, PhDc, Yeon Seok Seo, MD, PhDa, Dong Sik Kim, MD, PhDd, Hyonggin An, PhDe, Yun Hwan Kim, MD, PhDb Abstract To compare the diagnostic performance of gadoxetic acid-enhanced magnetic resonance imaging (MRI) with that of computed tomography (CT) during hepatic arteriography and arterial portography (CT HA/AP) for detecting hepatocellular carcinoma (HCC) from small hypervascular nodules. This retrospective study included 38 patients with 131 hypervascular nodules (2cm) who had underwent MRI and CT HA/AP within a 2-week interval. Two observers analyzed MRI while other 2 observers analyzed CT HA/AP. Thereafter, MRI observers reviewed the CT HA/AP and magnetic resonance (MR) images again using both modalities. HCC was diagnosed by pathologic or imaging studies according to American Association for the Study of Liver Diseases (AASLD) criteria. Alternative free-response receiver operating characteristic (ROC) analysis was performed on a lesion-by-lesion basis. Diagnostic accuracy (area under the ROC curve [Az]), sensitivity, specificity, and positive and negative predictive values were calculated. The pooled Az was significantly higher for the combined modalities (0.946) than for MRI alone (0.9, P=0.004), and for MRI than for CT HA/AP alone (0.827, P=0.0154).
    [Show full text]
  • Manual on Contrast Media Version 7 2010
    MANUAL ON CONTRAST MEDIA VERSION 7 2010 Quality is our Image™ Table of Contents TOPIC Preface ............................................................................................................................... Introduction ....................................................................................................................... Patient Selection and Preparation Strategies ...................................................................... Injection of Contrast Media ................................................................................................ Extravasation of Contrast Media ....................................................................................... Incidence of Adverse Effects .............................................................................................. Adverse Effects of Iodinated Contrast Media .................................................................... Contrast Nephrotoxicity ..................................................................................................... Metformin ........................................................................................................................ Contrast Media in Children ............................................................................................... Iodinated Gastrointestinal Contrast Media: Indications and Guidelines ............................. Adverse Reactions to Gadolinium-Based Contrast Media ................................................. Nephrogenic Systemic Fibrosis
    [Show full text]
  • 1 Non-Immediate Maculopapular Erythema to Gadolinium-Based
    1 Non-Immediate Maculopapular Erythema To Gadolinium-Based Contrast Agent Gauthier A1,2*, Mankouri F1*, Demoly P1,3, Chiriac AM1,3 1Department of Pulmonology, Division of Allergy, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Univ Montpellier, France 2Department of Allergy and Immunology, Laval University Hospital Center, Laval University, Quebec City, Canada 3Institut Desbrest d’Epidémiologie et de Santé Publique UMR INSERM - Université de Montpellier *These authors have contributed ex aequo. Corresponding author Dr Amélie GAUTHIER Laval University: Universite Laval Québec, QC Canada E-mail: [email protected] This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.18176/jiaci.0733 J Investig Allergol Clin Immunol 2022; Vol. 32(3) © 2021 Esmon Publicidad doi: 10.18176/jiaci.0733 2 Key words: Non-immediate hypersensitivity reactions. Gadolinium based contrast agents. Non- immediate hypersensitivity reaction investigation. Palabras clave: Reacciones no inmediatas de hipersensibilidad. Contrastes basados en gadolinio. Investigación de reacciones no inmediatas de hipersensibilidad. Gadolinium-based contrast agents (GBCA) are used to enhance tissue contrast during magnetic resonance imaging (MRI). They can be classified according to ionicity as ionic or non-ionic, or according to their molecular structure as macrocyclic or linear. GBCA are considered safer than iodinated contrast media (ICM), eliciting less immediate hypersensitivity (IHS) reactions (<1h after exposure).On the other hand, non-immediate HS reactions (NIHS, >1h after exposure) to ICM are well known and described, but this is not the case for NIHS reactions to GBCA.
    [Show full text]